



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Xingwei Di
✉ dxwww0929@163.com

RECEIVED 27 May 2025
ACCEPTED 11 June 2025
PUBLISHED 27 June 2025

CITATION

Jiang J, Zhong Q, Zhou X, Zhou L, Zheng J, Liu B and Di X (2025) Correction: Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system. *Front. Cardiovasc. Med.* 12:1636315. doi: 10.3389/fcvm.2025.1636315

COPYRIGHT

© 2025 Jiang, Zhong, Zhou, Zhou, Zheng, Liu and Di. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system

Jiazhen Jiang¹, Qian Zhong², Xinyu Zhou¹, Lisi Zhou³, Jiyuan Zheng¹, Bingshuo Liu⁴ and Xingwei Di^{5*}

¹The First Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China, ²Department of Cardiovascular Medicine, First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China, ³Clinical Medical College of Acupuncture, Moxibustion and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China, ⁴The Fifth Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China, ⁵Department of Cardiovascular Medicine, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China

KEYWORDS

amlodipine, adverse drug reactions, FDA adverse event reporting system, risk signal detection, logistic regression

A Correction on

Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system

By Jiang J, Zhong Q, Zhou X, Zhou L, Zheng J, Liu B and Di X (2025). *Front. Cardiovasc. Med.* 12:1504671. doi: 10.3389/fcvm.2025.1504671

The order of authors in the author list of the published paper was erroneously given as: Xingwei Di, Jiazhen Jiang, Qian Zhong, Xinyu Zhou, Lisi Zhou, Jiyuan Zheng, and Bingshuo Liu. The correct author list reads: Jiazhen Jiang, Qian Zhong, Xinyu Zhou, Lisi Zhou, Jiyuan Zheng, Bingshuo Liu and Xingwei Di. The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.